Categories
Pharmaceutical

Growing Government Initiative to Develop Innovative Therapeutics will Boost the Demand of Acute Hepatic Porphyria (APH) Market

250 Pages Acute Hepatic Porphyria (APH) Market Survey by Fact MR, A Leading Business and Competitive Intelligence Provider

Porphyria is aninborn error of heme biosynthesis, classified into 8 genetically distinct metabolic disorders.Heme is a component of hemoglobin, the oxygen carrier protein in the blood.Acute hepatic porphyria (APH) is one of the rare and significantly females dominated subtype of porphyrias, primarily affect the nervous system. In the United States, the prevalence of porphyria is approximated to be 1 in 25,000 individuals and the prevalence of clinical APHis reported to be 5 to 10 per 100,000 individuals.Drug therapies used to treatacute hepatic porphyria (APH) includes intravenous hemin, nutrition and hydration supplement, and anti-epileptic drugs. For life-threatening acute attacks liver transplantation may be required.

 

The Market Research Survey by Fact.MR, highlights the key reasons behind increasing demand and sales of Acute Hepatic Porphyria (APH). Acute Hepatic Porphyria (APH) market drivers and constraints, threats and opportunities, regional segmentation and opportunity assessment, end-use/application prospects review are addressed in the Acute Hepatic Porphyria (APH) market survey report. The survey report provides a comprehensive analysis of Acute Hepatic Porphyria (APH) market key trends and insights on Acute Hepatic Porphyria (APH) market size and share.

To Get In-depth Insights Request for Sample here – https://www.factmr.com/connectus/sample?flag=S&rep_id=4696

Acute Hepatic Porphyria (APH)Market: Segmentation

The acute hepatic porphyria (APH)market can besegmented into indication, drug type, distribution channels and geography.

Based on indication, the global acute hepatic porphyria (APH)market is segmented as:

  • Acute intermittent Porphyria (AIP)
  • Variagate Porphyria (VP)
  • Hereditary Coproporphyria (HC)
  • Hereditary Deficit of Delta-aminolevulinic Acid Dehydratase (HDAD)

Based on drug type, the global acute hepatic porphyria (APH)market is segmented as:

  • Intravenous Hemin
  • Carbohydrate Nutrition and Hydration
  • Hypertonic Saline
  • Anti-epileptics (Short-acting)

Based on the distribution channels, the global acute hepatic porphyria (APH)market is segmented as:

  • Hospital Pharmacies
  • Drug Stores
  • Retail Pharmacies
  • Online Pharmacies

Key questions answered in Acute Hepatic Porphyria (APH) Market Survey Report:

  1. What is the current scenario and key trends in Acute Hepatic Porphyria (APH) Market?
  2. What are the key strategies companies are adopting to increase their consumer base?
  3. What are the key categories within the Acute Hepatic Porphyria (APH) segments and their future potential?
  4. What are the major Acute Hepatic Porphyria (APH) Market drivers and their expected impact during the short, medium, and long terms?
  5. What is the Acute Hepatic Porphyria (APH) Market size and what are the opportunities for the key players?

Request Customized Report as Per Your Requirements – https://www.factmr.com/connectus/sample?flag=RC&rep_id=4696

Acute Hepatic porphyria (APH)Market: Key Players

The global market for acute hepatic porphyria (APH)is consolidated withlarge number of market players. Examples of some of the primary key players operating in the global acute hepatic porphyria (APH)market are Recordati Rare Diseases Inc., Lundbeck Inc., andAlnylam Pharmaceuticals, Inc.

The report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain. The report provides an in-depth analysis of parent market trends, macroeconomic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.

Essential Takeaways from the this Market Report

  • Comparison of prominent players operating in the market.
  • Recent developments and key strategies adopted by key players.
  • Study of the micro and macro-economic growth indicators.
  • Impact of the various factors on the value chain.
  • Evaluation of current Acute Hepatic Porphyria (APH) market size, forecast and technological advancements within the industry.
  • Current Insights influencing the scenario and key trends in Acute Hepatic Porphyria (APH) market.

Get Access to TOC Covering 200+ Topics- https://www.factmr.com/connectus/sample?flag=T&rep_id=4696

The Report Covers Exhaustive Analysis On:

  • Acute Hepatic Porphyria (APH) Market Drivers, Segments and Restraints.
  • Acute Hepatic Porphyria (APH) Market Survey and Dynamics
  • Acute Hepatic Porphyria (APH) Market Size & Demand
  • Acute Hepatic Porphyria (APH) Key Trends/Issues/Challenges
  • Acute Hepatic Porphyria (APH) Sales, Competition & Companies involved

Explore Fact.MR’s Coverage on the Healthcare Domain:

Autopsy Saw MarketAutopsy Saw Market Forecast, Trend Analysis & Competition Tracking-Global Market Insights 2018 to 2028

Deaver Retractor MarketDeaver Retractor Market Forecast, Trend Analysis & Competition Tracking-Global Market insights 2018 to 2028

Cataract Disposable Products MarketCataract Disposable Products Market Forecast, Trend Analysis & Competition Tracking-Global Market Insights 2018 to 2028

About Fact.MR

Market research and consulting agency with a difference! That’s why 80% of Fortune 1,000 companies trust us for making their most critical decisions. We have offices in US and Dublin, whereas our global headquarter is in Dubai. While our experienced consultants employ the latest technologies to extract hard-to-find insights, we believe our USP is the trust clients have on our expertise. Spanning a wide range – from automotive & industry 4.0 to healthcare & retail, our coverage is expansive, but we ensure even the most niche categories are analyzed. Reach out to us with your goals, and we’ll be an able research partner.

Contact:
US Sales Office:
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583
E-Mail: sales@factmr.com

Corporate Headquarter:
Unit No: AU-01-H Gold Tower (AU),
Plot No: JLT-PH1-I3A,
Jumeirah Lakes Towers,
Dubai, United Arab Emirates

Categories
Pharmaceutical

Increasing Acute Intermittent Porphyria (AIP) Incidence Rates to Widen Acute Hepatic Porphyria Expansion Prospects : Report Fact.MR

 

Award winning consulting firm Fact.MR’s ongoing acute hepatic porphyria (APH) market study forecasts a relatively positive outlook through 2021 and beyond, on the back of increasing demand for advanced therapeutic approaches for treating metabolic disorders. The market received a significant boost amidst the COVID-19 pandemic as well.

According to the National Center for Biotechnology Information, global prevalence of acute hepatic porphyria is projected to range from one in 500 to one in 50,000 individuals. The presence of clinical acute intermittent porphyria is reported to be 5 to 10 per 100,000 individuals, while prevalence of genetic mutations of AIP is around 1 in 1675 individuals. Such high prevalence rate is likely to drive demand for treating APH in forthcoming years.

Request Brochure- https://www.factmr.com/connectus/sample?flag=B&rep_id=4696

As per Fact.MR’s study, the acute hepatic porphyria market is expecting to witness credible developments with respect to availability of novel therapeutic drugs. In 2019, for instance, the US Food & Drug Administration (FDA) approved Givosiran (Givlaari) for adults with acute hepatic porphyrias. Givosiran is a small-interfering RNA that causes degradation of aminolevulinate synthase 1 (ALAS1) mRNA in hepatocytes through RNA interference, reducing elevated levels via subcutaneous injection.

Key Takeaways from Fact.MR’s Hepatic Porphyria (APH) Market Study

  • Acute Intermittent Porphyria (AIP) treatment to emerge as the dominant indication type
  • By drug type, intravenous hemin administration to remain the preferred route
  • Hospital pharmacies to be the primary distribution channel for major acute hepatic porphyria drugs
  • US to be a potential AHP drug market, attributed to swift drug candidate approvals by the FDA
  • Asymptomatic manifestation of the disease to fuel accelerated research on advanced AHP detection in the UK
  • Germany and France to open new expansion frontiers amid increasing healthcare spending

Acute Hepatic Porphyria (APH) Market- Prominent Drivers

  • Rapid advancements in metabolic disorders diagnostics is likely to propel acute hepatic porphyria market growth
  • Increasing regulatory approvals to admit possible life saving therapeutic approaches is widening growth scope
  • Strong government support for funding advanced research is providing major boost to APH therapeutics

Acute Hepatic Porphyria (APH) Market- Key Restraints

  • Limited awareness and inadequate access to quality healthcare in developing regions is limiting uptake
  • Asymptomatic manifestation of the disorder causes delays in diagnosis, restricting uptake

Request Customization- https://www.factmr.com/connectus/sample?flag=RC&rep_id=4696

Competitive Landscape

The global acute hepatic porphyria (APH) market comprises of the following key players: Recordati Rare Diseases Inc., Lundbeck Inc., Alleviare Life Sciences Pvt. Ltd., and Alnylam Pharmaceuticals, Inc. to name a few. The aforementioned players primarily concentrate on offering advanced drug formulations which are approved by key regulatory authorities.

Moreover, some players are also involved in offering resources to better understand disease onset and prognosis. For example, Alnylam Pharmaceuticals Inc., offers the PinpointAHP® platform. This forum provides patients and caregivers a variety of resources to help them understand the types of acute hepatic porphyria and recognize the signs and symptoms.

Also, manufacturers are in tandem with government initiatives to rein in the incidence of prominent rare disorders. For instance, Recordation Rare Diseases Inc. is supporting the European Porphyria Network in developing information for patients and families. This helps individuals detect signs early on and take effective preventive measures to mitigate its impact.

More Insights on the Acute Hepatic Porphyria (APH) Market

The research study on the acute hepatic porphyria (APH) market by Fact.MR includes an in-depth analysis of major demand-driving factors and trends and a comprehensive evaluation of crucial aspects that are projected to carve growth. Market statistics have been elucidated based on indication (acute intermittent porphyria (AIP), variegate porphyria (VP), hereditary coproporphyria (HC) and hereditary deficit of delta-aminolevulinic acid dehydratase (HDAD) drug type (intravenous hemin, carbohydrate nutrition and hydration, hypertonic saline and anti-epileptics (short-acting)) and distribution channel (hospital pharmacies, drug stores, retail pharmacies and online pharmacies) across seven major regions (North America, Latin America, Europe, East Asia, South Asia, Oceania and Middle East & Africa).

Explore Fact.MR’s Coverage on the Healthcare Domain: 

Leukocyte Count Testing Market – According to the latest research by Fact.MR, the leukocyte count testing market is set to witness exponential growth with over 7%-8% CAGR during 2021-2031. Increasing bacterial infection with the growing adoption of point of care devices will witness a promising growth outlook for leukocyte count testing in the long run.

At-Home Celiac Testing Market – According to the Latest Research by the Fact.MR The Celiac Testing market is set to gain growth in the forecast period 2021-2031 at a CAGR of 8.0%. The Reason for the growth is The increase in prevalence of Celiac disease globally.

Polysaccharide Hemostatic System Market – According to the latest research by Fact.MR, Polysaccharide Hemostatic System market is set to witness upsurge growth during the year 2021-2031.

About Fact.MR

Market research and consulting agency with a difference! That’s why 80% of Fortune 1,000 companies trust us for making their most critical decisions. While our experienced consultants employ the latest technologies to extract hard-to-find insights, we believe our USP is the trust clients have on our expertise. Spanning a wide range – from automotive & industry 4.0 to healthcare & retail, our coverage is expansive, but we ensure even the most niche categories are analyzed. Our sales offices in United States and Dublin, Ireland. Headquarter based in Dubai, UAE. Reach out to us with your goals, and we’ll be an able research partner. 

Contact:
US Sales Office:
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583
E Mail : sales@factmr.com

Corporate Headquarter:
Unit No: AU-01-H Gold Tower (AU),
Plot No: JLT-PH1-I3A,
Jumeirah Lakes Towers,
Dubai, United Arab Emirates
Visit Our Website: https://www.factmr.com

Categories
Pharmaceutical

Increasing Acute Intermittent Porphyria (AIP) Incidence Rates to Widen Acute Hepatic Porphyria Expansion Prospects : Report Fact.MR

Award winning consulting firm Fact.MR’s ongoing acute hepatic porphyria (APH) market study forecasts a relatively positive outlook through 2021 and beyond, on the back of increasing demand for advanced therapeutic approaches for treating metabolic disorders. The market received a significant boost amidst the COVID-19 pandemic as well.

According to the National Center for Biotechnology Information, global prevalence of acute hepatic porphyria is projected to range from one in 500 to one in 50,000 individuals. The presence of clinical acute intermittent porphyria is reported to be 5 to 10 per 100,000 individuals, while prevalence of genetic mutations of AIP is around 1 in 1675 individuals. Such high prevalence rate is likely to drive demand for treating APH in forthcoming years.

Request Brochure- https://www.factmr.com/connectus/sample?flag=B&rep_id=4696

As per Fact.MR’s study, the acute hepatic porphyria market is expecting to witness credible developments with respect to availability of novel therapeutic drugs. In 2019, for instance, the US Food & Drug Administration (FDA) approved Givosiran (Givlaari) for adults with acute hepatic porphyrias. Givosiran is a small-interfering RNA that causes degradation of aminolevulinate synthase 1 (ALAS1) mRNA in hepatocytes through RNA interference, reducing elevated levels via subcutaneous injection.

Key Takeaways from Fact.MR’s Hepatic Porphyria (APH) Market Study

  • Acute Intermittent Porphyria (AIP) treatment to emerge as the dominant indication type
  • By drug type, intravenous hemin administration to remain the preferred route
  • Hospital pharmacies to be the primary distribution channel for major acute hepatic porphyria drugs
  • US to be a potential AHP drug market, attributed to swift drug candidate approvals by the FDA
  • Asymptomatic manifestation of the disease to fuel accelerated research on advanced AHP detection in the UK
  • Germany and France to open new expansion frontiers amid increasing healthcare spending

Acute Hepatic Porphyria (APH) Market- Prominent Drivers

  • Rapid advancements in metabolic disorders diagnostics is likely to propel acute hepatic porphyria market growth
  • Increasing regulatory approvals to admit possible life saving therapeutic approaches is widening growth scope
  • Strong government support for funding advanced research is providing major boost to APH therapeutics

Acute Hepatic Porphyria (APH) Market- Key Restraints

  • Limited awareness and inadequate access to quality healthcare in developing regions is limiting uptake
  • Asymptomatic manifestation of the disorder causes delays in diagnosis, restricting uptake

Request Customization- https://www.factmr.com/connectus/sample?flag=RC&rep_id=4696

Competitive Landscape

The global acute hepatic porphyria (APH) market comprises of the following key players: Recordati Rare Diseases Inc., Lundbeck Inc., Alleviare Life Sciences Pvt. Ltd., and Alnylam Pharmaceuticals, Inc. to name a few. The aforementioned players primarily concentrate on offering advanced drug formulations which are approved by key regulatory authorities.

Moreover, some players are also involved in offering resources to better understand disease onset and prognosis. For example, Alnylam Pharmaceuticals Inc., offers the PinpointAHP® platform. This forum provides patients and caregivers a variety of resources to help them understand the types of acute hepatic porphyria and recognize the signs and symptoms.

Also, manufacturers are in tandem with government initiatives to rein in the incidence of prominent rare disorders. For instance, Recordation Rare Diseases Inc. is supporting the European Porphyria Network in developing information for patients and families. This helps individuals detect signs early on and take effective preventive measures to mitigate its impact.

More Insights on the Acute Hepatic Porphyria (APH) Market

The research study on the acute hepatic porphyria (APH) market by Fact.MR includes an in-depth analysis of major demand-driving factors and trends and a comprehensive evaluation of crucial aspects that are projected to carve growth. Market statistics have been elucidated based on indication (acute intermittent porphyria (AIP), variegate porphyria (VP), hereditary coproporphyria (HC) and hereditary deficit of delta-aminolevulinic acid dehydratase (HDAD) drug type (intravenous hemin, carbohydrate nutrition and hydration, hypertonic saline and anti-epileptics (short-acting)) and distribution channel (hospital pharmacies, drug stores, retail pharmacies and online pharmacies) across seven major regions (North America, Latin America, Europe, East Asia, South Asia, Oceania and Middle East & Africa).

Explore Fact.MR’s Coverage on the Healthcare Domain: 

Leukocyte Count Testing Market – According to the latest research by Fact.MR, the leukocyte count testing market is set to witness exponential growth with over 7%-8% CAGR during 2021-2031. Increasing bacterial infection with the growing adoption of point of care devices will witness a promising growth outlook for leukocyte count testing in the long run.

At-Home Celiac Testing Market – According to the Latest Research by the Fact.MR The Celiac Testing market is set to gain growth in the forecast period 2021-2031 at a CAGR of 8.0%. The Reason for the growth is The increase in prevalence of Celiac disease globally.

Polysaccharide Hemostatic System Market – According to the latest research by Fact.MR, Polysaccharide Hemostatic System market is set to witness upsurge growth during the year 2021-2031.

About Fact.MR

Market research and consulting agency with a difference! That’s why 80% of Fortune 1,000 companies trust us for making their most critical decisions. While our experienced consultants employ the latest technologies to extract hard-to-find insights, we believe our USP is the trust clients have on our expertise. Spanning a wide range – from automotive & industry 4.0 to healthcare & retail, our coverage is expansive, but we ensure even the most niche categories are analyzed. Our sales offices in United States and Dublin, Ireland. Headquarter based in Dubai, UAE. Reach out to us with your goals, and we’ll be an able research partner. 

Contact:
US Sales Office:
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583
E Mail : sales@factmr.com

Corporate Headquarter:
Unit No: AU-01-H Gold Tower (AU),
Plot No: JLT-PH1-I3A,
Jumeirah Lakes Towers,
Dubai, United Arab Emirates
Visit Our Website: https://www.factmr.com

Categories
Pharmaceutical

Increasing Acute Intermittent Porphyria (AIP) Incidence Rates to Widen Acute Hepatic Porphyria Expansion Prospects 2031

Award winning consulting firm Fact.MR’s ongoing acute hepatic porphyria (APH) market study forecasts a relatively positive outlook through 2021 and beyond, on the back of increasing demand for advanced therapeutic approaches for treating metabolic disorders. The market received a significant boost amidst the COVID-19 pandemic as well.

According to the National Center for Biotechnology Information, global prevalence of acute hepatic porphyria is projected to range from one in 500 to one in 50,000 individuals. The presence of clinical acute intermittent porphyria is reported to be 5 to 10 per 100,000 individuals, while prevalence of genetic mutations of AIP is around 1 in 1675 individuals. Such high prevalence rate is likely to drive demand for treating APH in forthcoming years.

Request Brochure- https://www.factmr.com/connectus/sample?flag=B&rep_id=4696

As per Fact.MR’s study, the acute hepatic porphyria market is expecting to witness credible developments with respect to availability of novel therapeutic drugs. In 2019, for instance, the US Food & Drug Administration (FDA) approved Givosiran (Givlaari) for adults with acute hepatic porphyrias. Givosiran is a small-interfering RNA that causes degradation of aminolevulinate synthase 1 (ALAS1) mRNA in hepatocytes through RNA interference, reducing elevated levels via subcutaneous injection.

Key Takeaways from Fact.MR’s Hepatic Porphyria (APH) Market Study

  • Acute Intermittent Porphyria (AIP) treatment to emerge as the dominant indication type
  • By drug type, intravenous hemin administration to remain the preferred route
  • Hospital pharmacies to be the primary distribution channel for major acute hepatic porphyria drugs
  • US to be a potential AHP drug market, attributed to swift drug candidate approvals by the FDA
  • Asymptomatic manifestation of the disease to fuel accelerated research on advanced AHP detection in the UK
  • Germany and France to open new expansion frontiers amid increasing healthcare spending

Acute Hepatic Porphyria (APH) Market- Prominent Drivers

  • Rapid advancements in metabolic disorders diagnostics is likely to propel acute hepatic porphyria market growth
  • Increasing regulatory approvals to admit possible life saving therapeutic approaches is widening growth scope
  • Strong government support for funding advanced research is providing major boost to APH therapeutics

Acute Hepatic Porphyria (APH) Market- Key Restraints

  • Limited awareness and inadequate access to quality healthcare in developing regions is limiting uptake
  • Asymptomatic manifestation of the disorder causes delays in diagnosis, restricting uptake

Request Customization- https://www.factmr.com/connectus/sample?flag=RC&rep_id=4696

Competitive Landscape

The global acute hepatic porphyria (APH) market comprises of the following key players: Recordati Rare Diseases Inc., Lundbeck Inc., Alleviare Life Sciences Pvt. Ltd., and Alnylam Pharmaceuticals, Inc. to name a few. The aforementioned players primarily concentrate on offering advanced drug formulations which are approved by key regulatory authorities.

Moreover, some players are also involved in offering resources to better understand disease onset and prognosis. For example, Alnylam Pharmaceuticals Inc., offers the PinpointAHP® platform. This forum provides patients and caregivers a variety of resources to help them understand the types of acute hepatic porphyria and recognize the signs and symptoms.

Also, manufacturers are in tandem with government initiatives to rein in the incidence of prominent rare disorders. For instance, Recordation Rare Diseases Inc. is supporting the European Porphyria Network in developing information for patients and families. This helps individuals detect signs early on and take effective preventive measures to mitigate its impact.

More Insights on the Acute Hepatic Porphyria (APH) Market

The research study on the acute hepatic porphyria (APH) market by Fact.MR includes an in-depth analysis of major demand-driving factors and trends and a comprehensive evaluation of crucial aspects that are projected to carve growth. Market statistics have been elucidated based on indication (acute intermittent porphyria (AIP), variegate porphyria (VP), hereditary coproporphyria (HC) and hereditary deficit of delta-aminolevulinic acid dehydratase (HDAD) drug type (intravenous hemin, carbohydrate nutrition and hydration, hypertonic saline and anti-epileptics (short-acting)) and distribution channel (hospital pharmacies, drug stores, retail pharmacies and online pharmacies) across seven major regions (North America, Latin America, Europe, East Asia, South Asia, Oceania and Middle East & Africa).

Free Mindfulness Meditation Apps to Gain Trajectory Boost during 2021-2031 – https://www.youtube.com/watch?v=MCEzxHyNzHc

About Fact.MR

Market research and consulting agency with a difference! That’s why 80% of Fortune 1,000 companies trust us for making their most critical decisions. While our experienced consultants employ the latest technologies to extract hard-to-find insights, we believe our USP is the trust clients have on our expertise. Spanning a wide range – from automotive & industry 4.0 to healthcare & retail, our coverage is expansive, but we ensure even the most niche categories are analyzed. Our sales offices in United States and Dublin, Ireland. Headquarter based in Dubai, UAE. Reach out to us with your goals, and we’ll be an able research partner. 

Contact:
US Sales Office:
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583
E Mail : sales@factmr.com

Corporate Headquarter:
Unit No: AU-01-H Gold Tower (AU),
Plot No: JLT-PH1-I3A,
Jumeirah Lakes Towers,
Dubai, United Arab Emirates

Visit Our Website: https://www.factmr.com